{"id":10423,"date":"2022-11-18T23:56:00","date_gmt":"2022-11-18T15:56:00","guid":{"rendered":"https:\/\/www.granitefirm.com\/blog\/us\/?p=10423"},"modified":"2025-11-07T11:30:34","modified_gmt":"2025-11-07T03:30:34","slug":"prescription-leader-abbvie","status":"publish","type":"post","link":"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/","title":{"rendered":"The next No. 1 pharmaceutical leader AbbVie"},"content":{"rendered":"\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #ffffff;color:#ffffff\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #ffffff;color:#ffffff\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#AbbVie_discussion_in_my_books\" >AbbVie discussion in my books<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Company_profile\" >Company profile<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Business_Overview\" >Business Overview<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Bad_news\" >Bad news<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Good_news\" >Good news<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#The_Acquisition_of_Allergan\" >The Acquisition of Allergan<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#How_is_the_performance_vs_peers\" >How is the performance vs. peers?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#business_performance_comparison\" >business performance comparison<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Stock_price_comparison\" >Stock price comparison<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Stock_performance_comparision\" >Stock performance comparision<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Business_outlook\" >Business outlook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Dividends\" >Dividends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Outlook_for_the_next_few_years\" >Outlook for the next few years<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/#Related_articles\" >Related articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AbbVie_discussion_in_my_books\"><\/span>AbbVie discussion in my books<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>I have discussed the company AbbVie (ticker: ABBV),  relative industry or topics, in my latest two books; including:<\/p>\n\n\n\n<p>In my book &#8220;<a href=\"https:\/\/www.books.com.tw\/products\/0010889106?sloc=main\" target=\"_blank\" rel=\"noreferrer noopener\">The Rules of Super Growth Stocks Investing<\/a>&#8220;:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Section 2-3, page 103, discussion on patents<\/li>\n<\/ul>\n\n\n\n<p>In my book &#8220;<a href=\"https:\/\/www.books.com.tw\/products\/0010935641?sloc=main\" target=\"_blank\" rel=\"noreferrer noopener\">The Rules of 10 Baggers<\/a>&#8220;:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sections 3-4, pp. 143-154, discussion on the healthcare and pharma<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Company_profile\"><\/span>Company profile<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AbbVie&#8217;s (ticker: ABBV) parent company, Abbott (ticker: ABT), was founded in 1888 by Wallace C. Abbott(I discussed Abbott in my previous post&#8221;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/07\/02\/abbott-laboratories\/\" target=\"_blank\" rel=\"noreferrer noopener\">Abbott, the world&#8217;s most important medical device and nutritional food supplier, how does it make money?<\/a>&#8220;). Then in 2013, Abbott&#8217;s pharmaceutical division was spun off and became an independent listed company AbbVie. So far, Abbott and AbbVie, the two publicly traded companies, have been very successful, and each is considered one of the top leaders in the medical device and pharmaceutical fields.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Business_Overview\"><\/span>Business Overview<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bad_news\"><\/span>Bad news<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The better-known bad news about AbbVie is that revenue from its most important immune drug, Humira, is declining year over year. Biosimilar competition is taking its share of the market in Europe, and to make matters worse, biosimilars will enter the US market next year.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Good_news\"><\/span>Good news<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>But the good news: AbbVie has other drug products that could make up its revenue. AbbVie said it expects combined sales of two other immunotherapy drugs, Skyrizi and Rinvoq, to surpass Humira&#8217;s top revenue. Both drugs could eventually be used for Humira&#8217;s indications. In the first quarter of 2022, Skyrizi&#8217;s sales increased by more than 63%, and Rinvoq&#8217;s sales increased by more than 53%.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Acquisition_of_Allergan\"><\/span>The Acquisition of Allergan<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AbbVie&#8217;s beauty line is also strengthening, thanks to <a href=\"https:\/\/www.financierworldwide.com\/abbvie-to-buy-allergan-in-63bn-deal#.YrRlWHZBw2w\" target=\"_blank\" rel=\"noreferrer noopener\">AbbVie&#8217;s $63 billion acquisition of Allergan<\/a>, known for its beauty products, in 2019. Allergan manufactures and sells the well-known anti-wrinkle product Botox and Juvederm, a filler for injectable gels. Shows beauty-related revenue growth of more than 20% in the first quarter of 2022 to $1.3 billion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_is_the_performance_vs_peers\"><\/span><strong>How is the performance vs. peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"business_performance_comparison\"><\/span>business performance comparison<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In 2021, Johnson&#8217;s and Johnson&#8217;s, Abbvie, Merck and Pfizer&#8217;s business performance are  shown in below table, respectively.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td>Index<\/td><td>JNJ<\/td><td>PFE<\/td><td>ABBV<\/td><td>MRK<\/td><\/tr><tr><td>2021 total revenue ($ billion)<\/td><td>93.775 +13.55%<\/td><td>81.288 +95%<\/td><td>56.197 +22.69%<\/td><td>48.704 +17.31%<\/td><\/tr><tr><td>Pharmaceuticals<\/td><td>52.08 +14.28%<\/td><td>79.557+95%<\/td><td>56.197 +22.69%<\/td><td>48.704 +17.31%<\/td><\/tr><tr><td>Medical devices \/ Pfizer is CDMO<\/td><td>27.06 +17.86%<\/td><td>1.731 +87%<\/td><td>0<\/td><td>0<\/td><\/tr><tr><td>Nutrition<\/td><td>14.645 +4.1%<\/td><td>0<\/td><td>Spin off as Abbott<\/td><td>Spin off as Organon<\/td><\/tr><tr><td>Gross margin<\/td><td>68.27%<\/td><td>62.28%<\/td><td>69.65%<\/td><td>72.81%<\/td><\/tr><tr><td>Operating margin<\/td><td>26.92%<\/td><td>33.02%<\/td><td>35.29%<\/td><td>32.56%<\/td><\/tr><tr><td>Net margin<\/td><td>22.26%<\/td><td>27.04%<\/td><td>22%<\/td><td>26.79%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Stock_price_comparison\"><\/span>Stock price comparison<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In the past 10 years, the stock prices of Johnson &amp; Johnson, Pfizer, Merck, and AbbVie, as shown in the chart below, have risen by 119.75%, 46.11%, 84.56%, 140.82%, and 297.71%, respectively.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"750\" height=\"383\" src=\"https:\/\/www.granitefirm.com\/blog\/us\/wp-content\/uploads\/sites\/2\/2022\/06\/s.png\" alt=\"\" class=\"wp-image-10715\" srcset=\"https:\/\/www.granitefirm.com\/blog\/us\/wp-content\/uploads\/sites\/2\/2022\/06\/s.png 750w, https:\/\/www.granitefirm.com\/blog\/us\/wp-content\/uploads\/sites\/2\/2022\/06\/s-300x153.png 300w\" sizes=\"auto, (max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 984px) 61vw, (max-width: 1362px) 45vw, 600px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-edbbd31e-25ac-446e-a21e-31142ee21ec3\"><span class=\"ez-toc-section\" id=\"Stock_performance_comparision\"><\/span><strong>Stock performance comparision<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td>\ufeff<\/td><td>JNJ<\/td><td>PFE<\/td><td>ABBV<\/td><td>MRK<\/td><\/tr><tr><td>Market captalization (billion)<\/td><td>474.54<\/td><td>277.14<\/td><td>259.43<\/td><td>221.61<\/td><\/tr><tr><td>Share price<\/td><td>180.46<\/td><td>49.07<\/td><td>146.88<\/td><td>87.65<\/td><\/tr><tr><td>P\/E<\/td><td>24.31<\/td><td>12.5<\/td><td>22.76<\/td><td>15.68<\/td><\/tr><tr><td>P\/S<\/td><td>5.08<\/td><td>3.51<\/td><td>4.91<\/td><td>4.1<\/td><\/tr><tr><td>Dividend yield<\/td><td>2.5%<\/td><td>3.26%<\/td><td>3.84%<\/td><td>3.15%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Business_outlook\"><\/span>Business outlook<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dividends\"><\/span>Dividends<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AbbVie is also the king of dividends, with a long-term dividend yield of nearly 4.1%, well above the market average of around 1.7%. Part of the reason why its long-term dividend yield is so high is that its top-selling drug Humira has seen revenue decline due to generic competition, leading to a depressed stock price.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"235\" height=\"52\" src=\"https:\/\/www.granitefirm.com\/blog\/us\/wp-content\/uploads\/sites\/2\/2022\/11\/a-1600x1200-1.jpg\" alt=\"AbbVie\" class=\"wp-image-15674\"\/><figcaption class=\"wp-element-caption\">credit:Wikimedia<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Outlook_for_the_next_few_years\"><\/span>Outlook for the next few years<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The company has two alternative medicines that AbbVie believes should make up for expected lost revenue, so its future still looks bright. Its quarterly revenue has grown more than 49% over the past three years, and its quarterly free cash flow has grown 195% over the same period. In addition, it has the largest total number of drugs in development pipeline, and multiple of these drug under development have been submitted to the FDA for review at the same time.<\/p>\n\n\n\n<p>Importantly, AbbVie is likely to continue to grow significantly even as Humira&#8217;s revenue declines. According to Statista, it is on track to become the No. 1 pharmaceutical company by global prescription drug market share by 2026.<\/p>\n\n\n\n<p>AbbVie has released results to investors. It has risen more than 80% over the past three years. But given future growth, there could be better underlying performance going forward. That&#8217;s why holding for the next decade might be a good idea for long-term investors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Related_articles\"><\/span>Related articles<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2025\/11\/06\/hca-healthcare\/\">How does HCA Healthcare make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2025\/10\/18\/chinese-biotech-deepseek\/\">Chinese biotech begins to show its DeepSeek moment<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2025\/09\/16\/akesos-beat-best-drug\/\">Akeso\u2019s lung cancer drug beat world best-selling drug, a biotech DeepSeek watershed<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/07\/weight-loss-is-golden-goose\/\">Weight loss is the future golden goose of the drug market<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/11\/02\/gene-editi-casgevy\/\">World\u2019s first gene editing therapy Casgevy finally approved<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/11\/17\/how-does-crispr-the-gene-editing-inventor-make-money\/\">How does CRISPR, the gene editing inventor, make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/28\/gilead-aids-vaccine\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gilead, lord of antiviral drug, reveals world&#8217;s first AIDS vaccine<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/06\/viking\/\" target=\"_blank\" rel=\"noreferrer noopener\">Viking is developing two future star new drugs at the same time<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/\" target=\"_blank\" rel=\"noreferrer noopener\">FDA approved first ever MASH drug<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/12\/07\/alzheimer-progress\/\" target=\"_blank\" rel=\"noreferrer noopener\">Alzheimer, the only major disease yet to be conquered, current progress and related companies<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/11\/15\/eli-lilly-value-king\/\" target=\"_blank\" rel=\"noreferrer noopener\">Why Eli Lilly become global pharmaceutical market value king?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/29\/big-pharma-spin-offs\/\">Big pharma spin-offs, and advantages to invest them<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/11\/29\/how-vertex-make-money\/\">How does rising biotech Vertex make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/09\/eli-lilly\/\">Eli Lilly, a big pharma with astonishing valuation<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/06\/22\/pfizer-the-largest-pharma\/\">Pfizer, the world&#8217;s largest pharmaceutical company<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/03\/30\/novo-nordisks-new-diabetes-drug-semaglutide-and-incretin-found-to-have-surprising-weight-loss-effects\/\">Novo Nordisk&#8217;s new diabetes drug Semaglutide,Ozempic,Wegovy and Mounjaro found to have surprising weight-loss effects<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/\">The next No. 1 pharmaceutical leader AbbVie<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/06\/24\/stable-dow-component-merck\/\">Stable Dow Component Merck, how does it make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/11\/06\/the-ex-largest-pharma-merck\/\" target=\"_blank\" rel=\"noreferrer noopener\">The ex-largest pharma Merck<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/07\/02\/abbott-laboratories\/\" target=\"_blank\" rel=\"noreferrer noopener\">Abbott, the world\u2019s most important medical device and nutritional food supplier, how does it make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/05\/17\/roche\/\">Roche, the king of anti-cancer<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/09\/21\/how-johnson-johnson-make-money\/\" target=\"_blank\" rel=\"noreferrer noopener\">How the best AAA credit rating Johnson &amp; Johnson makes money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/04\/04\/intuitive-surgical\/\">How does dominated Intuitive Surgical make money?&#8221;<\/a><\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/09\/eli-lilly\/\">Eli Lilly, a big pharma with astonishing valuation<\/a>&#8220;<\/li>\n<\/ul>\n\n\n\n<p><em><strong>Disclaimer<\/strong><\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>The content of this site is the author\u2019s personal opinions and is for reference only. I am not responsible for the correctness, opinions, and immediacy of the content and information of the article. Readers must make their own judgments.<\/em><\/li>\n\n\n\n<li><em>I shall not be liable for any damages or other legal liabilities for the direct or indirect losses caused by the readers&#8217; direct or indirect reliance on and reference to the information on this site, or all the responsibilities arising therefrom, as a result of any investment behavior.<\/em><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie&#8217;s (ticker: ABBV) parent company, Abbott (ticker: ABT), was founded in 1888 by Wallace C. Abbott. <\/p>\n","protected":false},"author":1,"featured_media":15674,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[120],"tags":[756,757,138,473,474],"class_list":["post-10423","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical","tag-abbv","tag-abt","tag-jnj","tag-mrk","tag-pfe"],"_links":{"self":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts\/10423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/comments?post=10423"}],"version-history":[{"count":31,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts\/10423\/revisions"}],"predecessor-version":[{"id":39820,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts\/10423\/revisions\/39820"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/media\/15674"}],"wp:attachment":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/media?parent=10423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/categories?post=10423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/tags?post=10423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}